{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:27:05Z","timestamp":1787740025497,"version":"build-2784847793"},"reference-count":421,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1100,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clinical use. Concurrent use of potassium-lowering agents may counteract hyperkalaemia and facilitate renin\u2013angiotensin\u2013aldosterone system inhibitor implementations. The results of the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) trial were confirmed by the Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER) trial, and we now have, for the first time, evidence for treatment of also patients with HF with preserved ejection fraction. In a pre-specified meta-analysis of major randomized controlled trials, sodium\u2013glucose co-transporter-2 inhibitors reduced all-cause mortality, cardiovascular (CV) mortality, and HF hospitalization in the patients with HF regardless of left ventricular ejection fraction. Other steps forward have occurred in the treatment of decompensated HF. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR) trial showed that the addition of intravenous acetazolamide to loop diuretics leads to greater decongestion vs. placebo. The addition of hydrochlorothiazide to loop diuretics was evaluated in the CLOROTIC trial. Torasemide did not change outcomes, compared with furosemide, in TRANSFORM-HF. Ferric derisomaltose had an effect on the primary outcome of CV mortality or HF rehospitalizations in IRONMAN (rate ratio 0.82; 95% confidence interval 0.66\u20131.02; P = 0.070). Further options for the treatment of HF, including device therapies, cardiac contractility modulation, and percutaneous treatment of valvulopathies, are summarized in this article.<\/jats:p>","DOI":"10.1002\/ehf2.14257","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:54:25Z","timestamp":1671695665000},"page":"3667-3693","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Heart Failure: An Update from the Last Years and a Look at the Near Future"],"prefix":"10.1093","volume":"9","author":[{"given":"Mauro","family":"Riccardi","sequence":"first","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Maria","family":"Sammartino","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Piepoli","sequence":"additional","affiliation":[{"name":"Clinical Cardiology, IRCCS Policlinico San Donato, University of Milan , Milan ,","place":["Italy"]},{"name":"Department of Preventive Cardiology, University of Wroc\u0142aw , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Roma , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University of Goettingen Medical Center , Gottingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner Site G\u00f6ttingen , Gottingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"2026012114133040200_ehf214257-bib-0001","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"Authors\/Task Force Members","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0003","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/ejhf.2018","article-title":"Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium","volume":"22","author":"Abraham","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0004","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0005","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1002\/ehf2.12979","article-title":"Epidemiology of heart failure: Study of Heart failure in the Australian Primary carE setting (SHAPE)","volume":"7","author":"Liew","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0006","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0007","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ejhf.1768","article-title":"The Heart Failure Association Atlas: rationale, objectives, and methods","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0008","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovic","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ejhf.1609","article-title":"Heart failure in Norway, 2000\u20132014: analysing incident, total and readmission rates using data from the Cardiovascular Disease in Norway (CVDNOR) Project","volume":"22","author":"Sulo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ejhf.1630","article-title":"Assessing the evidence\u2013practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics","volume":"22","author":"Li","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0011","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ejhf.1918","article-title":"Clinical course after a first episode of heart failure: insights from the Framingham Heart Study","volume":"22","author":"Velagaleti","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0012","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/ejhf.1800","article-title":"Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort","volume":"22","author":"Butt","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0013","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/ejhf.1968","article-title":"Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project","volume":"22","author":"Ishigami","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0014","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1645","article-title":"Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry","volume":"22","author":"Lainscak","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0015","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/ejhf.2005","article-title":"Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"22","author":"Ibrahim","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ejhf.1771","article-title":"Sex-related differences in contemporary biomarkers for heart failure: a review","volume":"22","author":"Suthahar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0017","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ejhf.1740","article-title":"Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials","volume":"22","author":"Rossello","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0018","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1002\/ehf2.13760","article-title":"A year in heart failure: an update of recent findings","volume":"8","author":"Stretti","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0019","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ejhf.2047","article-title":"Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men","volume":"23","author":"Stewart","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/eurjpc\/zwab078","article-title":"Sex differences on new-onset heart failure in patients with known or suspected coronary artery disease","volume":"28","author":"Nunez","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ejhf.1996","article-title":"National trends in heart failure mortality in men and women, United Kingdom, 2000\u20132017","volume":"23","author":"Taylor","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0022","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/ehf2.12815","article-title":"Sex differences in patients with acute decompensated heart failure in Japan: observation from the KCHF registry","volume":"7","author":"Yamamoto","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ejhf.2034","article-title":"Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review","volume":"23","author":"Whitelaw","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0024","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-022-10275-1","article-title":"Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients","author":"Wang","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026012114133040200_ehf214257-bib-0025","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/ejhf.2312","article-title":"Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial","volume":"23","author":"Blumer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0026","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1776","article-title":"Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0027","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/ejhf.1987","article-title":"Serum potassium in the PARADIGM-HF trial","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0028","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/ehf2.13925","article-title":"Prognostic significance of serum potassium in patients hospitalized for acute heart failure","volume":"9","author":"Lombardi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0029","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0030","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ehf2.12642","article-title":"Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post-discharge","volume":"7","author":"Rossignol","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0031","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ejhf.2024","article-title":"Effects of hyperkalaemia and non-adherence to renin\u2013angiotensin\u2013aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study","volume":"22","author":"Volterrani","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0032","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin\u2013angiotensin\u2013aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0033","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1724","article-title":"Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0034","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/2047487320957793","article-title":"Role of comorbidities in heart failure prognosis Part 2: chronic kidney disease, elevated serum uric acid","volume":"27","author":"Tedeschi","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0036","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/ejhf.1984","article-title":"Serum uric acid, influence of sacubitril\u2013valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF","volume":"22","author":"Selvaraj","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0037","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0038","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ejhf.2361","article-title":"Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis","volume":"23","author":"Vidula","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0039","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ejhf.2339","article-title":"Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Moura","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0040","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.1944","article-title":"Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review","volume":"22","author":"Henkens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0041","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ejhf.1660","article-title":"Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation","volume":"22","author":"Kuan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0042","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ehf2.13749","article-title":"N-terminal pro-B-type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction","volume":"9","author":"Januzzi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0043","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ejhf.2664","article-title":"Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology","volume":"24","author":"Nunez","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0044","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.1654","article-title":"Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0045","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/ejhf.2256","article-title":"Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0046","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ejhf.2102","article-title":"Relationship between body mass index, cardiovascular biomarkers and incident heart failure","volume":"23","author":"Suthahar","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0047","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/ejhf.2346","article-title":"Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)","volume":"23","author":"Meijers","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0048","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ejhf.1693","article-title":"Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission","volume":"22","author":"Pandhi","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0049","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ejhf.1437","article-title":"Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure","volume":"21","author":"Ter Maaten","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ejhf.1601","article-title":"Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics","volume":"22","author":"Deniau","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0051","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ejhf.2158","article-title":"Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin\u2013angiotensin\u2013aldosterone system in patients with heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0052","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ejhf.1600","article-title":"Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial","volume":"22","author":"Takagi","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0053","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ejhf.2201","article-title":"The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy\u2014a multilevel assessment of myocardial fibrosis in dilated cardiomyopathy","volume":"23","author":"Raafs","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0054","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ejhf.1749","article-title":"Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial","volume":"22","author":"Stohr","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0055","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ehf2.13758","article-title":"CA-125 variation in acute heart failure: a single-centre analysis","volume":"9","author":"Lourenco","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0056","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/ejhf.2295","article-title":"Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review","volume":"23","author":"Nunez","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0057","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ejhf.1642","article-title":"Short-term prognostic implications of serum and urine neutrophil gelatinase-associated lipocalin in acute heart failure: findings from the AKINESIS study","volume":"22","author":"Wettersten","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0058","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ejhf.2195","article-title":"Urinary peptides in heart failure: a link to molecular pathophysiology","volume":"23","author":"He","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0059","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/ejhf.1734","article-title":"Predictors of left ventricular remodelling in patients with dilated cardiomyopathy\u2014a cardiovascular magnetic resonance study","volume":"22","author":"Tayal","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0060","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/ejhf.1945","article-title":"Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction","volume":"22","author":"Yamanaka","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0061","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ejhf.1632","article-title":"Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment","volume":"22","author":"Nauta","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0062","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114133040200_ehf214257-bib-0063","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ejhf.1772","article-title":"Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial","volume":"22","author":"Janwanishstaporn","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0064","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/ehf2.12766","article-title":"The three-dimensional speckle tracking echocardiography in distinguishing between ischaemic and non-ischaemic aetiology of heart failure","volume":"7","author":"Vachalcova","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0065","first-page":"147","article-title":"Prognostic utility of diastolic dysfunction and speckle tracking echocardiography in heart failure with reduced ejection fraction","volume":"7","author":"Hansen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0066","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/ejhf.2315","article-title":"Layer-specific global longitudinal strain and the risk of heart failure and cardiovascular mortality in the general population: the Copenhagen City Heart Study","volume":"23","author":"Skaarup","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0067","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/ejhf.2161","article-title":"Change in ejection fraction and long-term mortality in adults referred for echocardiography","volume":"23","author":"Strange","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0068","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.2032","article-title":"Ultrasound imaging of congestion in heart failure: examinations beyond the heart","volume":"23","author":"Pellicori","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0069","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/ejhf.2353","article-title":"The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure","volume":"23","author":"Cuthbert","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ejhf.2125","article-title":"The significance of left ventricular ejection time in heart failure with reduced ejection fraction","volume":"23","author":"Alhakak","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0071","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ejhf.1659","article-title":"Association between systolic ejection time and outcomes in heart failure by ejection fraction","volume":"22","author":"Patel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0072","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/ejhf.2022","article-title":"Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction","volume":"23","author":"Alhakak","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0073","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ejhf.1643","article-title":"Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0074","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ejhf.1699","article-title":"Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction","volume":"22","author":"Tamargo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ehjci\/jeaa415","article-title":"Determinants of left atrial reservoir and pump strain and use of atrial strain for evaluation of left ventricular filling pressure","volume":"23","author":"Inoue","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114133040200_ehf214257-bib-0076","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.1829","article-title":"Central role of left atrial dynamics in limiting exercise cardiac output increase and oxygen uptake in heart failure: insights by cardiopulmonary imaging","volume":"22","author":"Sugimoto","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0077","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/ejhf.1820","article-title":"Impact of left atrial diameter on outcome in patients undergoing edge-to-edge mitral valve repair: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) registry","volume":"22","author":"Iliadis","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0078","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1002\/ehf2.13398","article-title":"Machine learning algorithms for claims data-based prediction of in-hospital mortality in patients with heart failure","volume":"8","author":"Konig","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0079","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ehf2.12795","article-title":"Biventricular imaging markers to predict outcomes in non-compaction cardiomyopathy: a machine learning study","volume":"7","author":"Rocon","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0080","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/ehf2.13358","article-title":"Derivation of an electronic frailty index for predicting short-term mortality in heart failure: a machine learning approach","volume":"8","author":"Ju","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0081","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ejhf.1628","article-title":"Improving risk prediction in heart failure using machine learning","volume":"22","author":"Adler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0082","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/ejhf.2155","article-title":"A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction","volume":"23","author":"Greenberg","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0083","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ejhf.2375","article-title":"Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia","volume":"24","author":"Segar","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0084","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ejhf.2144","article-title":"Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction","volume":"23","author":"Woolley","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0086","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin\u2013angiotensin\u2013aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0087","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab033","article-title":"Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?","volume":"7","author":"Ameri","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026012114133040200_ehf214257-bib-0088","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0089","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ejhf.1857","article-title":"Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0090","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/ehf2.13547","article-title":"Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis","volume":"8","author":"Giovinazzo","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0091","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","author":"Savarese","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0092","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ejhf.2163","article-title":"Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0093","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.2252","article-title":"Treatment patterns and clinical outcomes among patients &lt;65 years with a worsening heart failure event","volume":"23","author":"Butler","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0094","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ejhf.2160","article-title":"Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study)","volume":"23","author":"Gupta","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0095","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/ehf2.13223","article-title":"Adherence and optimization of angiotensin converting enzyme inhibitor\/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure","volume":"8","author":"Carubelli","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0096","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0097","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/ejhf.2572","article-title":"Sacubitril\/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of &gt;25 000 Medicare beneficiaries","volume":"24","author":"Bhatt","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0098","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ejhf.2206","article-title":"Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Rosano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0099","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0101","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ejhf.2259","article-title":"Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0102","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ejhf.2378","article-title":"Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction","volume":"23","author":"Seferovic","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0103","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0104","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/ejhf.1853","article-title":"Liver function and prognosis, and influence of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction","volume":"22","author":"Suzuki","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0105","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/ejhf.2355","article-title":"A randomized clinical trial on the short-term effects of 12-week sacubitril\/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study","volume":"23","author":"Halle","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0107","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/ejhf.1919","article-title":"Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril\/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction","volume":"22","author":"Edelmann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0108","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ehf2.13137","article-title":"Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling","volume":"8","author":"Docherty","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0111","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0112","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0113","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0114","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0116","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0117","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0118","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0119","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European Society of Cardiology\/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0120","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart Failure Association of the European Society of Cardiology update on sodium\u2013glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0121","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0122","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ejhf.1708","article-title":"Use of sodium\u2013glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0123","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026012114133040200_ehf214257-bib-0124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-8587(21)00292-8","article-title":"Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial","volume":"10","author":"Verma","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012114133040200_ehf214257-bib-0125","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/ejhf.2279","article-title":"Sodium\u2013glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism","volume":"23","author":"Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0126","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0127","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ejhf.2286","article-title":"Cardiac, renal, and metabolic effects of sodium\u2013glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium\u2013glucose co-transporter 2 inhibitors","volume":"23","author":"Herrington","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0128","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020348","article-title":"Prognostic benefit of new drugs for HFrEF: a systematic review and network meta-analysis","volume":"11","author":"Pagnesi","year":"2022","journal-title":"J Clin Med"},{"key":"2026012114133040200_ehf214257-bib-0129","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ejhf.2135","article-title":"Prevention of heart failure events with sodium\u2013glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk","volume":"23","author":"Bhatia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0130","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.2131","article-title":"Use of sodium\u2013glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0131","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.2073","article-title":"Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium\u2013glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58","volume":"23","author":"Zelniker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0132","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-Reduced trial","volume":"78","author":"Januzzi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0133","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/ejhf.2308","article-title":"Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index","volume":"23","author":"Adamson","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0134","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ejhf.1811","article-title":"A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure","volume":"22","author":"Sama","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0135","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ejhf.2124","article-title":"Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial","volume":"23","author":"Butt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0136","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2083","article-title":"Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF","volume":"23","author":"Dewan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0137","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0138","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ejhf.2386","article-title":"Patiromer for the management of hyperkalaemia in patients receiving renin\u2013angiotensin\u2013aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial","volume":"24","author":"Butler","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0139","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0140","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0141","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11886-021-01580-6","article-title":"Vericiguat for heart failure with reduced ejection fraction","volume":"23","author":"Lombardi","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"2026012114133040200_ehf214257-bib-0142","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0143","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ejhf.2285","article-title":"Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"23","author":"Ponikowski","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0144","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0146","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","article-title":"Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF","volume":"78","author":"Teerlink","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0147","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/ejhf.2015","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0148","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0149","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac293","article-title":"Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial","author":"Metra","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0150","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ehf2.13859","article-title":"Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care","volume":"9","author":"Tomasoni","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0151","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2022.11016","article-title":"Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial","volume":"328","author":"Lewis","year":"2022","journal-title":"JAMA"},{"key":"2026012114133040200_ehf214257-bib-0152","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0153","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/ehf2.12706","article-title":"Pharmacological inhibition of GRK2 improves cardiac metabolism and function in experimental heart failure","volume":"7","author":"Ciccarelli","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0154","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/ejhf.1809","article-title":"Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial","volume":"22","author":"Stewart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0155","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.1700","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial","volume":"22","author":"Mathiasen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0156","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13031","article-title":"Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes","author":"Bartunek","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0157","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ejhf.2178","article-title":"A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial","volume":"23","author":"Bolli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0158","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.1672","article-title":"Changes in m6A RNA methylation contribute to heart failure progression by modulating translation","volume":"22","author":"Berulava","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0159","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/ejhf.1813","article-title":"MiRNA-181a is a novel regulator of aldosterone\u2013mineralocorticoid receptor-mediated cardiac remodelling","volume":"22","author":"Garg","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ejhf.2008","article-title":"Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Jaarsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0161","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/ejhf.1746","article-title":"Anti-inflammatory diet and risk of heart failure: two prospective cohort studies","volume":"22","author":"Kaluza","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0162","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/ejhf.2278","article-title":"Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map","volume":"23","author":"Khan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0163","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/ejhf.2011","article-title":"Cachexia, muscle wasting, and frailty in cardiovascular disease","volume":"22","author":"Bielecka-Dabrowa","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0164","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ehf2.13213","article-title":"High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro-HEART trial","volume":"8","author":"Evangelista","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0165","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ejhf.2298","article-title":"The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease","volume":"23","author":"Aimo","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0166","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ejhf.2407","article-title":"Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?","volume":"24","author":"Nijholt","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0167","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ejhf.1838","article-title":"Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials","volume":"23","author":"von Haehling","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0168","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/ejhf.2594","article-title":"Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?","volume":"24","author":"Abdelhamid","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0169","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ejhf.1694","article-title":"Predictors of sudden cardiac death in high-risk patients following a myocardial infarction","volume":"22","author":"Docherty","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ejhf.1755","article-title":"One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System","volume":"22","author":"Fudim","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0171","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/ehf2.12654","article-title":"Acute correction of electromechanical dyssynchrony and response to cardiac resynchronization therapy","volume":"7","author":"Moubarak","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0172","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/ehf2.12940","article-title":"Cardiac resynchronization therapy in New York Heart Association class-IV patients dependent on intravenous drugs or invasive supportive treatments","volume":"7","author":"Lee","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0173","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0174","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ejhf.2046","article-title":"Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: a joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0175","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/ejhf.1374","article-title":"Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0176","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ejhf.1349","article-title":"Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond","volume":"21","author":"Tschope","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0177","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ehf2.12902","article-title":"A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life","volume":"7","author":"Giallauria","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0178","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/ejhf.2202","article-title":"Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system","volume":"23","author":"Kuschyk","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0179","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/ejhf.2276","article-title":"Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF","volume":"23","author":"Pagnesi","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0180","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ejhf.1830","article-title":"Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis","volume":"22","author":"Messika-Zeitoun","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0181","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/ejhf.1841","article-title":"Impact of recent heart failure hospitalization on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the PARTNER 2 trial and registries","volume":"22","author":"Chen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0182","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ejhf.1491","article-title":"Treatment of functional mitral regurgitation in chronic heart failure: can we get a \u2018proof of concept\u2019 from the MITRA-FR and COAPT trials?","volume":"21","author":"Senni","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0183","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ejhf.1469","article-title":"Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0184","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/ejhf.2097","article-title":"The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease","volume":"23","author":"Gill","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0185","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2613","article-title":"Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation","author":"Higuchi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0186","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0187","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/eurheartj\/ehab086","article-title":"The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC","volume":"42","author":"Coats","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0188","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/ejhf.2159","article-title":"Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and residual mitral regurgitation after MitraClip implantation","volume":"23","author":"Bedogni","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0189","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/ejhf.1774","article-title":"The impact of residual mitral regurgitation after MitraClip therapy in functional mitral regurgitation","volume":"22","author":"Reichart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0190","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/ejhf.2565","article-title":"Left atrial volume index and outcome after transcatheter edge-to-edge valve repair for secondary mitral regurgitation","volume":"24","author":"Iliadis","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0191","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/ejhf.2316","article-title":"Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation","volume":"23","author":"Caiffa","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0192","article-title":"Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality","author":"Adamo","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0193","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/ehf2.12750","article-title":"MitraClip and left ventricular reverse remodelling: a strain imaging study","volume":"7","author":"Papadopoulos","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0194","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/ejhf.2162","article-title":"Centre procedural volume and adverse in-hospital outcomes in patients undergoing percutaneous transvenous edge-to-edge mitral valve repair using MitraClip\u00ae in Germany","volume":"23","author":"Keller","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0195","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/ejhf.2310","article-title":"Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation","volume":"23","author":"Witte","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0196","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/ejhf.2321","article-title":"Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation","volume":"23","author":"Patterson","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0197","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ejhf.2398","article-title":"Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?","volume":"24","author":"Russo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0198","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/eurheartj\/ehab679","article-title":"TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery","volume":"43","author":"Dreyfus","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0199","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1002\/ehf2.12992","article-title":"Edge-to-edge tricuspid valve repair for severe tricuspid regurgitation 20 years after cardiac transplantation","volume":"7","author":"Misumida","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0200","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ehf2.12577","article-title":"Transcatheter edge-to-edge tricuspid repair for recurrence of valvular regurgitation after left ventricular assist device and tricuspid ring implantation","volume":"7","author":"Andreas","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0201","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/ejhf.1752","article-title":"Nutritional status in tricuspid regurgitation: implications of transcatheter repair","volume":"22","author":"Besler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0202","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/ejhf.2307","article-title":"Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis","volume":"23","author":"Unterhuber","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0203","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.1788","article-title":"Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0204","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.13124","article-title":"Heart failure in the last year: progress and perspective","author":"Tomasoni","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0205","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ejhf.1741","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA\u2013PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Pieske","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0206","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/ejhf.2169","article-title":"Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction","volume":"23","author":"Uijl","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0207","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2459\/JCM.0000000000001366","article-title":"Right and left ventricular structures and functions in acute HFpEF: comparing the hypertensive pulmonary edema and worsening heart failure phenotypes","volume":"23","author":"Iacovoni","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012114133040200_ehf214257-bib-0208","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ejhf.2345","article-title":"Heart failure with preserved ejection fraction after left-sided valve surgery: prevalent and relevant","volume":"23","author":"Kammerlander","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0209","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.1646","article-title":"Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0210","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.2440","article-title":"Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer","volume":"24","author":"Omar","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0211","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ejhf.1902","article-title":"Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0212","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/ejhf.2291","article-title":"Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction","volume":"23","author":"Kresoja","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0213","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ehf2.13081","article-title":"Heart failure development in obesity: underlying risk factors and mechanistic pathways","volume":"8","author":"Jamaly","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0214","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ejhf.1961","article-title":"Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities","volume":"22","author":"Quarta","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0215","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ejhf.1956","article-title":"Regional adiposity and heart failure with preserved ejection fraction","volume":"22","author":"Rao","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0216","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ejhf.2156","article-title":"Epicardial fat in heart failure with reduced versus preserved ejection fraction","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0217","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"van Woerden","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0218","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ejhf.1617","article-title":"Myocardial adipose deposition and the development of heart failure with preserved ejection fraction","volume":"22","author":"Wu","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0219","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/ejhf.2337","article-title":"Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure","volume":"23","author":"Pugliese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0220","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/eurjpc\/zwaa117","article-title":"Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction","volume":"28","author":"Konishi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0221","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ejhf.2254","article-title":"Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction","volume":"23","author":"Sorimachi","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0222","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ejhf.1671","article-title":"Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"22","author":"Yang","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0223","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ejhf.2010","article-title":"Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction","volume":"23","author":"Ahmad","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0224","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","author":"Pugliese","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026012114133040200_ehf214257-bib-0225","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ejhf.1638","article-title":"Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard","volume":"22","author":"Myhre","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0226","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1161\/CIRCULATIONAHA.118.038594","article-title":"External validation of the H2F-PEF model in diagnosing patients with heart failure and preserved ejection fraction","volume":"139","author":"Sepehrvand","year":"2019","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0227","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ejhf.2019","article-title":"The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction","volume":"23","author":"Sanders-van Wijk","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0228","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ejhf.1614","article-title":"Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction","volume":"22","author":"Barandiaran Aizpurua","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0229","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0230","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/ejhf.1851","article-title":"Heart failure with preserved ejection fraction diagnostic scores in an Asian population","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0231","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ejhf.2142","article-title":"Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction","volume":"23","author":"Verbrugge","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0232","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/ehf2.13532","article-title":"Applying the ESC 2016, H2FPEF, and HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population","volume":"8","author":"Nikorowitsch","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0233","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/ehf2.13288","article-title":"Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems","volume":"8","author":"Parcha","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0234","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2616","article-title":"Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0235","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ejhf.2601","article-title":"Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy\u2014a clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology","volume":"24","author":"Guazzi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0236","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ejhf.1739","article-title":"Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test","volume":"22","author":"Pugliese","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0237","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0238","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/ehjci\/jeab266","article-title":"Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study","volume":"23","author":"Raisi-Estabragh","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114133040200_ehf214257-bib-0239","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/ehjci\/jeac036","article-title":"Left atrial reservoir strain improves diagnostic accuracy of the 2016 ASE\/EACVI diastolic algorithm in patients with preserved left ventricular ejection fraction: insights from the KARUM haemodynamic database","volume":"23","author":"Venkateshvaran","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114133040200_ehf214257-bib-0240","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0241","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0242","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"2026012114133040200_ehf214257-bib-0243","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0244","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0245","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ejhf.2093","article-title":"Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction","volume":"23","author":"Reddy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0246","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/ejhf.2487","article-title":"Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0247","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/ejhf.2122","article-title":"A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF","volume":"23","author":"Sugumar","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0248","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/ejhf.2360","article-title":"Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis","volume":"23","author":"Lauder","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0249","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/ejhf.2119","article-title":"One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study","volume":"23","author":"Paitazoglou","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0250","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ejhf.2184","article-title":"Interatrial shunting for the treatment of heart failure: an on-demand, self-regulating left atrial pressure lowering system","volume":"23","author":"Abraham","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0251","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"2026012114133040200_ehf214257-bib-0252","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1093\/eurheartj\/ehy682","article-title":"Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF","volume":"39","author":"Fudim","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0253","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.118.035260","article-title":"Splanchnic nerve block for acute heart failure","volume":"138","author":"Fudim","year":"2018","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0254","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.2196","article-title":"Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations","volume":"23","author":"Fudim","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0255","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/ejhf.2209","article-title":"Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first-in-human clinical trial","volume":"23","author":"Malek","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0256","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/ejhf.2559","article-title":"Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort","volume":"24","author":"Fudim","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0257","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","article-title":"Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?","volume":"41","author":"Wehner","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0258","article-title":"Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction","author":"van Essen","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0259","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2482","article-title":"Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure","author":"Forrest","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0260","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jchf.2022.05.007","article-title":"Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: findings from population-based cohort studies","volume":"10","author":"Shah","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0261","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ejhf.1818","article-title":"Trends in prevalence of comorbidities in heart failure clinical trials","volume":"22","author":"Khan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0262","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ejhf.1971","article-title":"Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy","volume":"23","author":"Vaduganathan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0263","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ejhf.1666","article-title":"Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation","volume":"22","author":"Polovina","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0264","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial","volume":"22","author":"Bohm","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0265","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ejhf.1735","article-title":"Genetic risk and atrial fibrillation in patients with heart failure","volume":"22","author":"Kloosterman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0266","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ejhf.1790","article-title":"Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome","volume":"22","author":"Shin","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0267","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.1795","article-title":"The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial\u2014insights from ASCEND-HF","volume":"22","author":"Bhatt","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0268","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/ejhf.1832","article-title":"The prevalence and importance of frailty in heart failure with reduced ejection fraction\u2014an analysis of PARADIGM-HF and ATMOSPHERE","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0269","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ejhf.2177","article-title":"Cognitive impairment as a determinant of response to management plans after heart failure admission","volume":"23","author":"Huynh","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0270","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ejhf.1926","article-title":"Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE-HF cohort study","volume":"22","author":"Matsue","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0271","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ejhf.1865","article-title":"Depression and heart failure: the lonely comorbidity","volume":"22","author":"Sbolli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0272","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2253","article-title":"Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients","volume":"23","author":"Tkaczyszyn","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0273","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ejhf.2251","article-title":"Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure","volume":"24","author":"Graham","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0274","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ehf2.12797","article-title":"Anaemia, iron deficiency and heart failure in 2020: facts and numbers","volume":"7","author":"Chopra","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0275","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/ehf2.13204","article-title":"Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction","volume":"8","author":"Barandiaran Aizpurua","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0276","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026012114133040200_ehf214257-bib-0277","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ejhf.2630","article-title":"Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0278","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/ejhf.2338","article-title":"Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0279","article-title":"Iron deficiency and cardiovascular disease","author":"Savarese","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0280","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ejhf.2036","article-title":"High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality","volume":"23","author":"Sierpinski","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0281","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0282","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0283","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0284","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2026012114133040200_ehf214257-bib-0285","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0286","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-022-10251-9","article-title":"Combined pre- and post-capillary pulmonary hypertension in left heart disease","author":"Riccardi","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026012114133040200_ehf214257-bib-0287","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.011430","article-title":"Prognostic importance of right ventricular-vascular uncoupling in acute decompensated heart failure with preserved ejection fraction","volume":"13","author":"Nakagawa","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114133040200_ehf214257-bib-0288","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0289","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008726","article-title":"Right ventricular and right atrial function are less compromised in pulmonary hypertension secondary to heart failure with preserved ejection fraction: a comparison with pulmonary arterial hypertension with similar pressure overload","volume":"15","author":"van Wezenbeek","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ejhf.1679","article-title":"Pulmonary artery pulsatility index: physiological basis and clinical application","volume":"22","author":"Lim","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0291","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ejhf.1862","article-title":"Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors","volume":"22","author":"Santiago-Vacas","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0292","first-page":"253","article-title":"Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension","volume":"7","author":"Patel","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0293","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/cvr\/cvab342","article-title":"European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1\u2014epidemiology, pathophysiology, and diagnosis","volume":"118","author":"Task Force for the Management of COVID-19 of the European Society of Cardiology","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026012114133040200_ehf214257-bib-0294","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.713560","article-title":"COVID-19 and heart failure: from epidemiology during the pandemic to myocardial injury, myocarditis, and heart failure sequelae","volume":"8","author":"Italia","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012114133040200_ehf214257-bib-0295","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2459\/JCM.0000000000001098","article-title":"Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction","volume":"21","author":"Tomasoni","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012114133040200_ehf214257-bib-0296","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ejhf.2044","article-title":"In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network","volume":"22","author":"Konig","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0297","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/ejhf.1986","article-title":"Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London","volume":"22","author":"Cannata","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0298","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1093\/eurheartj\/ehac227","article-title":"The collateral damage of COVID-19 to cardiovascular services: a meta-analysis","volume":"43","author":"Nadarajah","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0299","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ejhf.1925","article-title":"The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic","volume":"22","author":"Bromage","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0300","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/ejhf.2052","article-title":"Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study","volume":"22","author":"Tomasoni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0301","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/ejhf.1871","article-title":"COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease","volume":"22","author":"Tomasoni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0302","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/ejhf.1990","article-title":"Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications","volume":"22","author":"Rey","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0303","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/ejhf.2020","article-title":"Angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease","volume":"22","author":"Lebek","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0304","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0305","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ejhf.2060","article-title":"Association between renin\u2013angiotensin\u2013aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0306","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s00392-020-01766-y","article-title":"Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study","volume":"110","author":"Ameri","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0307","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/europace\/euab146","article-title":"Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study","volume":"23","author":"Paris","year":"2021","journal-title":"Europace"},{"key":"2026012114133040200_ehf214257-bib-0308","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ejhf.2095","article-title":"Characterization of NT-proBNP in a large cohort of COVID-19 patients","volume":"23","author":"Caro-Codon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0309","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amjcard.2021.11.054","article-title":"Combined role of troponin and natriuretic peptides measurements in patients with Covid-19 (from the Cardio-COVID-Italy multicenter study)","volume":"167","author":"Iorio","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0310","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/ehf2.13548","article-title":"Admission NT-proBNP and outcomes in patients without history of heart failure hospitalized with COVID-19","volume":"8","author":"Yoo","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0311","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/ejhf.2347","article-title":"Recovery of cardiac function following COVID-19\u2014ECHOVID-19: a prospective longitudinal cohort study","volume":"23","author":"Lassen","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0312","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11897-021-00509-y","article-title":"Myocardial involvement in COVID-19: an interaction between comorbidities and heart failure with preserved ejection fraction. A further indication of the role of inflammation","volume":"18","author":"Zaccone","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"2026012114133040200_ehf214257-bib-0313","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.2210","article-title":"Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings","volume":"23","author":"Hadzibegovic","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0314","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/ejhf.2326","article-title":"Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection","volume":"23","author":"Lambadiari","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0315","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamacardio.2020.2159","article-title":"Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019","volume":"5","author":"Latif","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0316","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/ejhf.2199","article-title":"Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients\u2014a prospective cohort study","volume":"23","author":"Itzhaki Ben Zadok","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0317","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/ejhf.1915","article-title":"Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Zhang","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0318","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/eurheartj\/ehab697","article-title":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2\u2014care pathways, treatment, and follow-up","volume":"43","author":"Task Force for the Management of COVID-19 of the European Society of Cardiology","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0319","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/eurheartj\/ehab696","article-title":"European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1\u2014epidemiology, pathophysiology, and diagnosis","volume":"43","author":"Task Force for the Management of COVID-19 of the European Society of Cardiology","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0320","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.hfc.2021.05.003","article-title":"Congestion in patients with advanced heart failure: assessment and treatment","volume":"17","author":"Lombardi","year":"2021","journal-title":"Heart Fail Clin"},{"key":"2026012114133040200_ehf214257-bib-0321","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ejhf.2561","article-title":"Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry","volume":"24","author":"Pagnesi","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0322","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40265-021-01666-z","article-title":"Contemporary drug treatment of advanced heart failure with reduced ejection fraction","volume":"82","author":"Vishram-Nielsen","year":"2022","journal-title":"Drugs"},{"key":"2026012114133040200_ehf214257-bib-0323","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0324","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/eurheartj\/ehac204","article-title":"Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies","volume":"43","author":"Crespo-Leiro","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0325","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1002\/ehf2.12995","article-title":"Age and shock severity predict mortality in cardiac intensive care unit patients with and without heart failure","volume":"7","author":"Padkins","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0326","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically modified porcine-to-human cardiac xenotransplantation","volume":"387","author":"Griffith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0327","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/ejhf.2327","article-title":"Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary","volume":"23","author":"Ben Gal","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0328","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ejhf.1773","article-title":"Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial","volume":"22","author":"Karason","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0329","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1610426","article-title":"A fully magnetically levitated circulatory pump for advanced heart failure","volume":"376","author":"Mehra","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0330","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ejhf.2211","article-title":"Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants","volume":"23","author":"Mehra","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0331","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/CIRCHEARTFAILURE.111.962142","article-title":"Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling","volume":"4","author":"Kato","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0332","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ejhf.2021","article-title":"Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with end-stage heart failure","volume":"23","author":"Kassner","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0333","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/ejhf.1873","article-title":"Sacubitril\/valsartan in patients post-left ventricular assist device implant: a single-centre case series","volume":"22","author":"Randhawa","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0334","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ejhf.2215","article-title":"Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes","volume":"23","author":"Yuzefpolskaya","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0335","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/ejhf.2275","article-title":"Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial","volume":"23","author":"Mehra","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0336","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ejhf.1810","article-title":"Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0337","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ejhf.2154","article-title":"Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire","volume":"23","author":"Ravera","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0338","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ejhf.2141","article-title":"Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis","volume":"23","author":"Turgeon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0339","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ejhf.2277","article-title":"Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction","volume":"23","author":"Shah","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0340","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ejhf.1994","article-title":"Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper","volume":"22","author":"Hill","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0341","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ejhf.1783","article-title":"The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials","volume":"22","author":"Sahlollbey","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0342","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.pcad.2020.04.007","article-title":"Acute heart failure: more questions than answers","volume":"63","author":"Tomasoni","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012114133040200_ehf214257-bib-0343","first-page":"621","article-title":"Evidence-based management of acute heart failure","volume":"37","author":"Gupta","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0344","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1002\/ehf2.12847","article-title":"In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department","volume":"7","author":"Lombardi","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0345","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ejhf.1831","article-title":"Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Harjola","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0346","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ejhf.2030","article-title":"Frequency, trends and institutional variation in 30-day all-cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand","volume":"23","author":"Labrosciano","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0347","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ejhf.2077","article-title":"Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF","volume":"23","author":"Davison","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0348","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ejhf.1937","article-title":"Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failure","volume":"23","author":"Goetze","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0349","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ejhf.2012","article-title":"Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study","volume":"23","author":"Feng","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0350","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ejhf.2053","article-title":"Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients","volume":"23","author":"Biegus","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0351","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ejhf.2385","article-title":"Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial","volume":"24","author":"Ter Maaten","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0352","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ehf2.13089","article-title":"The prehospital patient pathway and experience of care with acute heart failure: a comparison of two health care systems","volume":"8","author":"McCambridge","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0353","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0354","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cardfail.2015.11.003","article-title":"Rationale and design of the \u201cSafety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure (CLOROTIC) trial:\u201d a double-blind, randomized, placebo-controlled study to determine the effect of combined diuretic therapy (loop diuretics with thiazide-type diuretics) among patients with decompensated heart failure","volume":"22","author":"Trullas","year":"2016","journal-title":"J Card Fail"},{"key":"2026012114133040200_ehf214257-bib-0355","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jchf.2021.01.013","article-title":"Pragmatic design of randomized clinical trials for heart failure: rationale and design of the TRANSFORM-HF trial","volume":"9","author":"Greene","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0356","volume-title":"Torsemide comparison with furosemide for management of heart failure\u2014TRANSFORM-HF","author":"Mentz","year":"2022"},{"key":"2026012114133040200_ehf214257-bib-0357","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026012114133040200_ehf214257-bib-0358","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0359","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026012114133040200_ehf214257-bib-0360","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2459\/JCM.0000000000001221","article-title":"Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice","volume":"23","author":"Rosano","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012114133040200_ehf214257-bib-0361","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"S0140-6736","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026012114133040200_ehf214257-bib-0362","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ejhf.1692","article-title":"Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0363","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/ejhf.1743","article-title":"Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial","volume":"22","author":"Carubelli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0364","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ejhf.2629","article-title":"Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock\u2014a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC)","volume":"24","author":"Metra","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0365","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ejhf.1667","article-title":"Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18","volume":"22","author":"Mockel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0366","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0367","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ejhf.1750","article-title":"Trends in cardiogenic shock complicating acute myocardial infarction","volume":"22","author":"Aissaoui","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0368","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/ejhf.2263","article-title":"Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world","volume":"23","author":"Lu","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0369","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/ejhf.2274","article-title":"Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials","volume":"23","author":"Schrage","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0370","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/cvr\/cvab343","article-title":"ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2\u2014care pathways, treatment, and follow-up","volume":"118","author":"Task Force for the Management of COVID-19 of the European Society of Cardiology","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026012114133040200_ehf214257-bib-0371","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ejhf.1906","article-title":"Telemonitoring versus standard care in heart failure: a randomised multicentre trial","volume":"22","author":"Galinier","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0372","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ejhf.2025","article-title":"Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study","volume":"23","author":"Koehler","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0373","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ejhf.2033","article-title":"A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure","volume":"23","author":"Bekfani","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0374","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ejhf.1709","article-title":"Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM-HF trial","volume":"22","author":"Zakeri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0375","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/ejhf.1970","article-title":"Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP-HF study","volume":"22","author":"van Veldhuisen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0376","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)","volume":"22","author":"Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0377","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/ejhf.1848","article-title":"Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients","volume":"22","author":"Almufleh","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0378","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/ejhf.1870","article-title":"Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0379","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jacc.2021.01.030","article-title":"Cardiac rehabilitation for patients with heart failure: JACC Expert Panel","volume":"77","author":"Bozkurt","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0380","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2026141","article-title":"Physical rehabilitation for older patients hospitalized for heart failure","volume":"385","author":"Kitzman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114133040200_ehf214257-bib-0381","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ejhf.2035","article-title":"Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology","volume":"23","author":"Klompstra","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0382","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0383","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.1758","article-title":"Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls","volume":"22","author":"Tromp","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0384","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ejhf.2071","article-title":"Advanced cancer is also a heart failure syndrome: a hypothesis","volume":"23","author":"Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0385","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ejhf.2059","article-title":"Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study","volume":"23","author":"Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0386","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ejhf.1847","article-title":"Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer","volume":"22","author":"Dobbin","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0387","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ejhf.1610","article-title":"Myocardial dysfunction in long-term breast cancer survivors treated at ages 40\u201350 years","volume":"22","author":"Jacobse","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0388","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ejhf.1620","article-title":"Heart failure after treatment for breast cancer","volume":"22","author":"Boekel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0389","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0390","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/ejhf.2303","article-title":"Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria","volume":"23","author":"Rizzo","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0391","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0392","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114133040200_ehf214257-bib-0393","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ejhf.2250","article-title":"Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy","volume":"23","author":"Restrepo-Cordoba","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0394","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0395","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/ejhf.2264","article-title":"Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry","volume":"23","author":"Jackson","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0396","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ejhf.1815","article-title":"The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy","volume":"22","author":"Finocchiaro","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0397","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1002\/ehf2.13568","article-title":"Prevalence, clinical and instrumental features of left bundle branch block-induced cardiomyopathy: the CLIMB registry","volume":"8","author":"Sanna","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0398","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ejhf.1914","article-title":"Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy","volume":"22","author":"Merlo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0399","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"2026012114133040200_ehf214257-bib-0400","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ejhf.2063","article-title":"Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF","volume":"23","author":"Halliday","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0401","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter","volume":"11","author":"Masri","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012114133040200_ehf214257-bib-0402","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0403","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0404","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","author":"Rosenblum","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0405","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC review topic of the week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0406","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ehjci\/jeac146","article-title":"Echocardiographic predictors of presence of cardiac amyloidosis in aortic stenosis","volume":"23","author":"Jaiswal","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114133040200_ehf214257-bib-0407","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/ehf2.12668","article-title":"Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition","volume":"7","author":"Randhawa","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0408","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0409","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ehf2.13093","article-title":"Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis","volume":"8","author":"Fagot","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0410","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ejhf.2016","article-title":"Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"23","author":"Nicol","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0411","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ejhf.1695","article-title":"Emerging therapies in transthyretin amyloidosis\u2014a new wave of hope after years of stagnancy?","volume":"22","author":"Muller","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0412","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature","volume":"8","author":"Adam","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0413","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"Bezard","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0414","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0415","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026012114133040200_ehf214257-bib-0416","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/ejhf.2288","article-title":"Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias","volume":"23","author":"Gentile","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0417","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/ejhf.2247","article-title":"Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab","volume":"23","author":"Ammirati","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0418","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2669","article-title":"Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases","author":"Heidecker","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0419","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ejhf.1969","article-title":"Viral presence-guided immunomodulation in lymphocytic myocarditis: an update","volume":"23","author":"Sinagra","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0420","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ejhf.2082","article-title":"Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double-blind, randomized, placebo-controlled clinical trial","volume":"23","author":"Hazebroek","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114133040200_ehf214257-bib-0421","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/ehf2.12887","article-title":"Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis","volume":"7","author":"Tschope","year":"2020","journal-title":"ESC Heart Fail"}],"updated-by":[{"DOI":"10.1002\/ehf2.14323","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000}}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14257","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14257","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/6\/3667\/65347692\/eschf_9_6_3667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/6\/3667\/65347692\/eschf_9_6_3667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:16:14Z","timestamp":1769022974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/6\/3667\/8322794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":421,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,22]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14257","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"2022-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}